WELCOME TO The HEALTHCARE REPORT
Healthcare Management Solutions Ltd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
3M | April 05, 2021
3M Health Information Systems has launched a new technology platform that enables health care professionals and payers to prioritize care and allocate services to high-risk individuals and patient groups. 3MTM Social Determinants of Health Analytics (3M SDoH) integrates clinical, social, and population health data to provide a comprehensive view of patient health. The new platform utilizes the strength o...
HealthPayerIntelligence | February 13, 2020
While access to care progress has stalled nationwide, payers can continue to move it forward within their own businesses by addressing four key barriers. Uninsurance is dropping, yet access to care continues to suffer due to rising health costs, a recent JAMA Internal Medicine study found. Nearly six percent more among the uninsured population did not access care due to affordability struggles and 11.5 percent of the insured avoided a doctor’s visit for the same reason. The trend was noted...
FUTURE OF HEALTHCARE
MedX Health Corp. | November 22, 2021
MedX Health Corp. (“MedX” or the “Company”) and Al Zahrawi Medical Supplies LLC ("Al Zahrawi") are pleased to announce a Memorandum of Understanding between the companies on a two-phase commercialization pilot and distribution agreement for MedX’s leading-edge DermSecure® Screening Platform at select United Arab Emirates (“UAE”) oncology and dermatology clinics beginning this month.
The three-month pilot will involve an e...
Medicago | May 06, 2022
Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills.
COVIFENZ® is indicated for active immunizatio...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE